Compare Stocks: INTS, NTRB, CLNN, and SCYX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$3.85 -3.5%	$5.15	$3.72 ▼ $13.50	$49.47M	0.95	96,670 shs	122,559 shs
INTS Intensity Therapeutics	$4.10 +2.5%	$4.40	$3.51 ▼ $43.50	$13.39M	2.76	35,959 shs	4,451 shs
NTRB Nutriband	$5.97 +6.0%	$3.47	$2.80 ▼ $8.63	$72.57M	2.03	37,696 shs	93,622 shs
SCYX SCYNEXIS	$5.30 -0.7%	$4.73	$3.53 ▼ $10.48	$52.73M	1.11	85,559 shs	55,491 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	0.00%	-8.98%	-27.90%	-29.36%	-31.13%
INTS Intensity Therapeutics	0.00%	-3.53%	-3.53%	+8.75%	-39.03%
NTRB Nutriband	0.00%	+33.86%	+104.45%	+66.76%	-5.98%
SCYX SCYNEXIS	0.00%	-1.67%	+1.92%	+12.53%	-21.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$3.85 -3.5%	$5.15	$3.72 ▼ $13.50	$49.47M	0.95	96,670 shs	122,559 shs
INTS Intensity Therapeutics	$4.10 +2.5%	$4.40	$3.51 ▼ $43.50	$13.39M	2.76	35,959 shs	4,451 shs
NTRB Nutriband	$5.97 +6.0%	$3.47	$2.80 ▼ $8.63	$72.57M	2.03	37,696 shs	93,622 shs
SCYX SCYNEXIS	$5.30 -0.7%	$4.73	$3.53 ▼ $10.48	$52.73M	1.11	85,559 shs	55,491 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	0.00%	-8.98%	-27.90%	-29.36%	-31.13%
INTS Intensity Therapeutics	0.00%	-3.53%	-3.53%	+8.75%	-39.03%
NTRB Nutriband	0.00%	+33.86%	+104.45%	+66.76%	-5.98%
SCYX SCYNEXIS	0.00%	-1.67%	+1.92%	+12.53%	-21.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLNN Clene	2.71	Moderate Buy	$33.25	763.64% Upside
INTS Intensity Therapeutics	2.80	Moderate Buy	$7.00	70.73% Upside
NTRB Nutriband	1.50	Reduce	N/A	N/A
SCYX SCYNEXIS	2.33	Hold	$33.00	522.64% Upside

Current Analyst Ratings Breakdown

Latest INTS, NTRB, CLNN, and SCYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	INTS Intensity Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $7.00
8/17/2026	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	SCYX SCYNEXIS	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$24.00 ➝ $33.00
8/11/2026	INTS Intensity Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	SCYX SCYNEXIS	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/30/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/24/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	INTS Intensity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLNN Clene	$200K	247.36	N/A	N/A	($1.93) per share	-1.99
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	$2.82 per share	N/A
NTRB Nutriband	$2.04M	35.59	N/A	N/A	$0.55 per share	10.85
SCYX SCYNEXIS	$20.60M	2.56	N/A	N/A	$6.73 per share	0.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLNN Clene	-$26.17M	-$3.50	N/A	N/A	N/A	-20,063.96%	N/A	-137.04%	11/12/2026 (Estimated)
INTS Intensity Therapeutics	-$11.61M	-$3.57	N/A	N/A	N/A	N/A	-116.61%	-94.01%	11/5/2026 (Estimated)
NTRB Nutriband	-$8.23M	-$0.53	N/A	N/A	N/A	-448.25%	-112.64%	-97.86%	9/30/2026 (Estimated)
SCYX SCYNEXIS	-$8.61M	-$2.09	N/A	N/A	N/A	-41.79%	-44.15%	-32.61%	11/4/2026 (Estimated)

Latest INTS, NTRB, CLNN, and SCYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q2 2027	NTRB Nutriband	N/A	-$0.07	N/A	-$0.07	N/A	$0.44 million
8/14/2026	Q2 2026	CLNN Clene	-$0.3680	-$1.08	-$0.7120	-$1.08	$0.06 million	$0.09 million
8/11/2026	Q2 2026	INTS Intensity Therapeutics	-$0.8725	-$1.11	-$0.2375	-$1.11	N/A	N/A
8/10/2026	Q2 2026	SCYX SCYNEXIS	-$0.5067	$0.63	+$1.1367	$0.63	$0.08 million	$0.24 million
6/11/2026	Q1 2027	NTRB Nutriband	N/A	-$0.10	N/A	-$0.10	N/A	$0.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLNN Clene	N/A	N/A	N/A	N/A	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLNN Clene	N/A	3.07	3.07
INTS Intensity Therapeutics	0.01	5.00	5.00
NTRB Nutriband	N/A	5.26	5.11
SCYX SCYNEXIS	N/A	9.65	9.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLNN Clene	23.28%
INTS Intensity Therapeutics	3.74%
NTRB Nutriband	19.70%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
CLNN Clene	28.30%
INTS Intensity Therapeutics	7.60%
NTRB Nutriband	52.21%
SCYX SCYNEXIS	4.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLNN Clene	100	12.85 million	9.21 million	No Data
INTS Intensity Therapeutics	2,021	3.26 million	3.02 million	Not Optionable
NTRB Nutriband	10	12.16 million	5.81 million	Not Optionable
SCYX SCYNEXIS	60	9.95 million	9.54 million	Optionable

INTS, NTRB, CLNN, and SCYX Headlines

Recent News About These Companies

SCYNEXIS to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below Two Hundred Day Moving Average - Here's What Happened

September 1, 2026 | americanbankingnews.com

SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average - Should You Sell?

September 1, 2026 | marketbeat.com

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

August 25, 2026 | globenewswire.com

SCYNEXIS (NASDAQ:SCYX) Upgraded at Wall Street Zen

August 16, 2026 | marketbeat.com

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 | tmcnet.com

SCYNEXIS (NASDAQ:SCYX) Announces Quarterly Earnings Results, Beats Expectations By $1.14 EPS

August 10, 2026 | marketbeat.com

SCYNEXIS (NASDAQ:SCYX) Lowered to Strong Sell Rating by Wall Street Zen

August 8, 2026 | marketbeat.com

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

June 30, 2026 | globenewswire.com

SCYNEXIS Shareholders Approve Governance and Equity Plan Changes

June 26, 2026 | tipranks.com

SCYNEXIS Inc.

June 24, 2026 | marketwatch.com

SCYNEXIS Announces One-for-Eight Reverse Stock Split

May 22, 2026 | globenewswire.com

SCYNEXIS (SCYX) price target increased by 20.73% to 4.28

May 14, 2026 | msn.com

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 11, 2026 | globenewswire.com

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2026 | globenewswire.com

SCYNEXIS Raises $40 Million in Strategic Private Placement

April 19, 2026 | theglobeandmail.com

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

March 31, 2026 | seekingalpha.com

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney ...

March 31, 2026 | markets.businessinsider.com

Why did SCYX stock jump 10% in pre-market today?

March 31, 2026 | msn.com

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

March 31, 2026 | businesswire.com

SCYNEXIS Announces $40.0 Million Private Placement

March 31, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INTS, NTRB, CLNN, and SCYX Company Descriptions

Clene NASDAQ:CLNN

$3.85 -0.14 (-3.51%)

As of 09/4/2026 04:00 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Intensity Therapeutics NASDAQ:INTS

$4.10 +0.10 (+2.50%)

As of 09/4/2026 04:00 PM Eastern

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Nutriband NASDAQ:NTRB

$5.97 +0.34 (+6.04%)

As of 09/4/2026 04:00 PM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

SCYNEXIS NASDAQ:SCYX

$5.30 -0.04 (-0.75%)

As of 09/4/2026 04:00 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INTS, NTRB, CLNN, and SCYX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INTS, NTRB, CLNN, and SCYX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INTS, NTRB, CLNN, and SCYX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INTS, NTRB, CLNN, and SCYX Company Descriptions

Clene NASDAQ:CLNN

Intensity Therapeutics NASDAQ:INTS

Nutriband NASDAQ:NTRB

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INTS, NTRB, CLNN, and SCYX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INTS, NTRB, CLNN, and SCYX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INTS, NTRB, CLNN, and SCYX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INTS, NTRB, CLNN, and SCYX Company Descriptions

Clene NASDAQ:CLNN

Intensity Therapeutics NASDAQ:INTS

Nutriband NASDAQ:NTRB

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools